Original Article

COVID-19 Trials: Who Participates and Who Benefits?

Authors: Shanti Narayanasamy, MBBS, Ahmad Mourad, MD, Nicholas A. Turner, MD, MHSc, Thuy Le, MD, PhD, Robert J. Rolfe, MD, Nwora Lance Okeke, MD, MPH, Sean M. O’Brien, PhD, Arthur W. Baker, MD, MPH, Rebekah Wrenn, PharmD, Rossana Rosa, MD, Frank W. Rockhold, PhD, Susanna Naggie, MD, Jason E. Stout, MD, MHS

Abstract

Objectives: The coronavirus disease 2019 (COVID-19) pandemic has disproportionately afflicted vulnerable populations. Older adults, particularly residents of nursing facilities, represent a small percentage of the population but account for 40% of mortality from COVID-19 in the United States. Racial and ethnic minority individuals, particularly Black, Hispanic, and Indigenous Americans have experienced higher rates of infection and death than the White population. Although there has been an unprecedented explosion of clinical trials to examine potential therapies, participation by members of these vulnerable communities is crucial to obtaining data generalizable to those communities.

Methods: We undertook an open-label, factorial randomized clinical trial examining hydroxychloroquine and/or azithromycin for hospitalized patients.

Results: Of 53 screened patients, 11 (21%) were enrolled. Ten percent (3/31) of Black patients were enrolled, 33% (7/21) of White patients, and 50% (6/12) of Hispanic patients. Forty-seven percent (25/53) of patients declined participation despite eligibility; 58%(18/31) of Black patients declined participation. Forty percent (21/53) of screened patients were from a nursing facility and 10% (2/21) were enrolled. Enrolled patients had fewer comorbidities than nonenrolled patients: median modified Charlson comorbidity score 2.0 (interquartile range 0–2.5), versus 4.0 (interquartile range 2–6) for nonenrolled patients (P = 0.006). The limitations of the study were the low participation rate and the multiple treatment trials concurrently recruiting at our institution.

Conclusions: The high rate of nonparticipation in our trial of nursing facility residents and Black people emphasizes the concern that clinical trials for therapeutics may not target key populations with high mortality rates.
Posted in: Infectious Disease143

Full Article

Having trouble viewing the article content below? Click here to open it directly.

Images

Download Image

Download Image

Download Image

References

1. Cytel. Global coronavirus COVID-19 clinical trial tracker. https://www. covid-trials.org. Accessed April 2, 2021.
 
2. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—final report. N Engl J Med 2020;383:1813–1826.
 
3. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med 2021;384:693–704.
 
4. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med 2021;384:229–237.
 
5. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med 2021;384: 238–251.
 
6. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 2021;384:795–807.
 
7. North CM, Dougan ML, Sacks CA. Improving clinical trial enrollment—in the Covid-19 era and beyond. N Engl J Med 2020;383:1406–1408.
 
8. Palmieri L, Vanacore N, Donfrancesco C, et al. Clinical characteristics of hospitalized individuals dying with COVID-19 by age group in Italy. J Gerontol A Biol Sci Med Sci 2020;75:1796–1800.
 
9. Neumann-Podczaska A, Al-Saad SR, Karbowski LM, et al. COVID 19— clinical picture in the elderly population: a qualitative systematic review. Aging Dis 2020;11:988–1008.
 
10. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–1062.
 
11. Lee JY, Kim HA, Huh K, et al. Risk factors for mortality and respiratory support in elderly patients hospitalized with COVID-19 in Korea. J Korean Med Sci 2020;35:e223.
   
13. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180:934–943.
 
14. Kluge HHP. Statement—older people are at highest risk from COVID-19, but all must act to prevent community spread. https://www.euro.who.int/en/ health-topics/health-emergencies/coronavirus-covid-19/statements/statementolder-people-are-at-highest-risk-from-covid-19,-but-all-must-act-to-preventcommunity-spread. Published April 2, 2020. Accessed January 15, 2022.
 
15. Centers for Disease Control and Prevention. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12- March 16, 2020. MMWR Morb Mortal Wkly Rep 2020;69:343–346.
 
16. Centers For Disease Control and Prevention. Weekly updates by select demographic and geographic characteristics. Provisional death counts for coronavirus disease 2019 (COVID-19). https://www.cdc.gov/nchs/nvss/ vsrr/covid_weekly/index.htm. Published 2020. Accessed January 2, 2021.
 
17. Ma Y, Hou L, Yang X, et al. The association between frailty and severe disease among COVID-19 patients aged over 60 years in China: a prospective cohort study. BMC Med 2020;18:274.
 
18. Machado CJ, Pereira CCA, Viana BM, et al. Estimates of the impact of COVID-19 on mortality of institutionalized elderly in Brazil. Cien Saude Colet 2020;25:3437–3444.
 
19. Ciminelli G, Garcia-Mandicó S. COVID-19 in Italy: an analysis of death registry data. J Public Health (Oxf ) 2020;42:723–730.
 
20. Barnett ML, Hu L, Martin T, et al. Mortality, admissions, and patient census at SNFs in 3 US cities during the COVID-19 pandemic. JAMA 2020;324: 507–509.
 
21. Kamp J, Mathews AW. As U.S. Nursing-Home Deaths Reach 50,000, States Ease Lockdowns, June 16th, 2020. Available at: https://www.wsj.com/ articles/coronavirus-deaths-in-u-s-nursing-long-term-care-facilities-top-50- 000-11592306919. Accessed February 28, 2022.
 
22. Herrera AP, Snipes SA, King DW, et al. Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am J Public Health 2010;100(suppl 1):S105–S112.
 
23. Centers for Disease Control and Prevention. COVID data tracker: demographic trends of COVID-19 cases and deaths in the US reported to CDC. https:// covid.cdc.gov/covid-data-tracker/#demographics. Published 2020. Accessed February 16, 2022.
 
24. Humes KR, Jones NA, Ramirez RR. Overview of race and Hispanic origin: 2010. https://www.census.gov/prod/cen2010/briefs/c2010br-02.pdf. Published March 2011. Accessed January 15, 2022.
 
25. Brosseau C. Coronavirus NC: deaths in long-term care, nursing homes rise. News & Observer, May 30, 2020.
 
26. Harris R, Dyson E. Recruitment of frail older people to research: lessons learnt through experience. J Adv Nurs 2001;36:643–651.
 
27. Galea S, Tracy M. Participation rates in epidemiologic studies. Ann Epidemiol 2007;17:643–653.
 
28. Warren RC, Shedlin MG, Alema-Mensah E, et al. Clinical trials participation among African Americans and the ethics of trust: leadership perspectives. Ethics Med Public Health 2019;10:128–138.
 
29. Katz RV, Warren RC, eds.. The Search for the Legacy of the USPHS Syphilis Study at Tuskegee. Lanham, MD: Lexington Books; 2013.
 
30. Washington HA. Medical Apartheid: The Dark History of Medical Experimentation on Black Americans from Colonial Times to the Present. New York: Doubleday; 2006.
 
31. Warren RC, Forrow L, Hodge DA, et al. Trustworthiness before trust— Covid-19 vaccine trials and the Black community. N Engl J Med 2020; 383:e121.
 
32. Hoffman J. ‘I won’t be used as a guinea pig for white people’. https://www. nytimes.com/2020/10/07/health/coronavirus-vaccine-trials-africanamericans.htmlhttps://www.nytimes.com/2020/10/07/health/coronavirusvaccine-trials-african-americans.html. Published October 7, 2020. Accessed January 15, 2022.
 
33. North Carolina Department of Health and Human Services. NC COVID-19 dashboard, outbreaks and clusters. https://Covid19.ncdhhs.gov/dashboard/ outbreaks-and-clusters. Published 2020. Accessed September 20, 2020.
 
34. National Institutes of Health. Revision: NIH policy and guidelines on the inclusion of individuals across the lifespan as participants in research involving human subjects. https://grants.nih.gov/news/revision-nih-policyand-guidelines-inclusion-individuals-across-lifespan-participantsresearch. Published December 26, 2017. Accessed January 15, 2022.
 
35. Helfand BKI, Webb M, Gartaganis SL, et al. The exclusion of older persons from vaccine and treatment trials for coronavirus disease 2019—missing the target. JAMA Intern Med 2020;180:1546–1549.
 
36. Stone W. Politics around hydroxychloroquine hamper science. https://www. npr.org/sections/health-shots/2020/05/21/859851682/politics-aroundhydroxychloroquine-hamper-science. Published 2010. Accessed October 10, 2020.
 
37. Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for Covid-19—interim WHO Solidarity Trial results. N Engl J Med 2021;384: 497–511.
 
38. OXFAM. Campaigners warn that 9 out of 10 people in poor countries are set to miss out on COVID-19 vaccine next year. https://www.oxfam.org/en/pressreleases/campaigners-warn-9-out-10-people-poor-countries-are-set-miss-outcovid-19-vaccine. Published December 9, 2020. Accessed January 15, 2022.